BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luo M, Chen L, He H, He F. Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib. Eur J Med Res 2022;27. [DOI: 10.1186/s40001-022-00693-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Ida T, Furuta S, Takayama A, Tamura J, Hayashi Y, Abe K, Kurihara S, Ishikawa J, Iwamoto T, Ikeda K, Suzuki K, Nakajima H. Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD Open 2023;9. [PMID: 36593080 DOI: 10.1136/rmdopen-2022-002795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tanboon J, Nishino I. Update on dermatomyositis. Curr Opin Neurol 2022. [PMID: 35942671 DOI: 10.1097/WCO.0000000000001091] [Reference Citation Analysis]
3 . Piperacillin/tazobactam/tofacitinib. Reactions Weekly 2022;1913:378-378. [DOI: 10.1007/s40278-022-18528-3] [Reference Citation Analysis]